Resources Archive - Cytoreason

CytoReason unveils LINA, an AI Agent accelerated by NVIDIA for Pharma R&D, built on computational disease models

TEL AVIV, Israel, Jan. 12, 2026 /PRNewswire/ — At the 2026 JP Morgan Healthcare Conference, CytoReason unveiled LINA, an AI agent designed to support pharmaceutical research and development. LINA is a computational biology assistant that interprets molecular, clinical, and patient-level data using CytoReason’s AI disease models and NVIDIA NIM microservices. Built on CytoReason’s AI framework and trained on hundreds of […]

CytoReason extends its collaboration with Sanofi to advance AI-driven drug discovery

This marks CytoReason’s fifth commercial deal of 2025 and builds on its track record with half of the world’s top twenty pharma companies, which have leveraged its technology across a range of programs. TEL AVIV, Israel, Jan. 9, 2026 /PRNewswire/ — CytoReason, a leader in AI-powered computational disease modeling, today announced the expansion of its collaboration with […]

Beyond Legacy Tools: Defining Modern AI Drug Discovery for 2025 and Beyond

Curating Biological Findings from Scientific Literature with NVIDIA NIM

How top pharma companies boost efficacy

CytoReason’s proven artificial intelligence-powered disease models and analytics platform are providing insights at scale. The probability of technical and regulatory success (PTRS) in drug development is around 8%1. The highest impact is the 36% probability of success in phase 2, impacted by limited efficacy. To increase efficacy success and thereby patient health and commercial outcomes, […]

Interactions between immune cell types facilitate the evolution of immune traits

Digital Health 50: The most promising digital health startups of 2024

CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts

Archives: Resources